AU2023264537A1 - Tetrahydroisoquinoline heterobifunctional bcl-xl degraders - Google Patents

Tetrahydroisoquinoline heterobifunctional bcl-xl degraders Download PDF

Info

Publication number
AU2023264537A1
AU2023264537A1 AU2023264537A AU2023264537A AU2023264537A1 AU 2023264537 A1 AU2023264537 A1 AU 2023264537A1 AU 2023264537 A AU2023264537 A AU 2023264537A AU 2023264537 A AU2023264537 A AU 2023264537A AU 2023264537 A1 AU2023264537 A1 AU 2023264537A1
Authority
AU
Australia
Prior art keywords
compound
cancer
group
alkyl
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023264537A
Other languages
English (en)
Inventor
Matthew D. Alexander
Joshua D. Hansen
Evan J. Horn
Fei Huang
Mark A. Nagy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Treeline Biosciences, Inc
Original Assignee
Treeline Biosciences, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Treeline Biosciences, Inc filed Critical Treeline Biosciences, Inc
Publication of AU2023264537A1 publication Critical patent/AU2023264537A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023264537A 2022-05-06 2023-05-04 Tetrahydroisoquinoline heterobifunctional bcl-xl degraders Pending AU2023264537A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202263339308P 2022-05-06 2022-05-06
US63/339,308 2022-05-06
US202263398752P 2022-08-17 2022-08-17
US63/398,752 2022-08-17
US202263429834P 2022-12-02 2022-12-02
US63/429,834 2022-12-02
US202363449728P 2023-03-03 2023-03-03
US63/449,728 2023-03-03
US202363454486P 2023-03-24 2023-03-24
US63/454,486 2023-03-24
PCT/US2023/020956 WO2023215449A1 (en) 2022-05-06 2023-05-04 Tetrahydroisoquinoline heterobifunctional bcl-xl degraders

Publications (1)

Publication Number Publication Date
AU2023264537A1 true AU2023264537A1 (en) 2024-11-14

Family

ID=86609470

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023264537A Pending AU2023264537A1 (en) 2022-05-06 2023-05-04 Tetrahydroisoquinoline heterobifunctional bcl-xl degraders

Country Status (7)

Country Link
US (1) US20250288683A1 (https=)
EP (1) EP4519272A1 (https=)
JP (1) JP2025516359A (https=)
AU (1) AU2023264537A1 (https=)
CA (1) CA3252016A1 (https=)
MX (1) MX2024013312A (https=)
WO (1) WO2023215449A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250197387A1 (en) * 2021-09-17 2025-06-19 Kymera Therapeutics, Inc. Bcl-xl degraders and uses thereof
WO2025036119A1 (zh) * 2023-08-11 2025-02-20 北京三秀生物医药科技有限公司 靶向Bcl-xL蛋白的PROTAC及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
US8889675B2 (en) 2011-10-14 2014-11-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN109152933B (zh) 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
ES3041854T3 (en) 2018-01-22 2025-11-17 Bioventures Llc Bcl-2 proteins degraders for cancer treatment
CN113660937A (zh) 2019-02-08 2021-11-16 佛罗里达大学研究基金公司 治疗剂和治疗方法
AU2020310147A1 (en) 2019-07-10 2022-01-06 Recurium Ip Holdings, Llc Bcl-2 protein inhibitors
CN112707900B (zh) 2019-10-24 2022-06-10 上海科技大学 蛋白降解剂及其在疾病治疗中的应用
US12441722B2 (en) 2020-01-15 2025-10-14 University Of Florida Research Foundation, Incorporated Therapeutic agents and methods of treatment
US20230167105A1 (en) 2020-04-28 2023-06-01 Recurium Ip Holdings, Llc Bcl-2 protein inhibitors
JP2024505562A (ja) 2021-02-02 2024-02-06 レス ラボラトイレス セルビエル 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法
US20250197387A1 (en) 2021-09-17 2025-06-19 Kymera Therapeutics, Inc. Bcl-xl degraders and uses thereof

Also Published As

Publication number Publication date
EP4519272A1 (en) 2025-03-12
US20250288683A1 (en) 2025-09-18
JP2025516359A (ja) 2025-05-27
WO2023215449A1 (en) 2023-11-09
CA3252016A1 (en) 2023-11-09
MX2024013312A (es) 2025-02-10

Similar Documents

Publication Publication Date Title
JP7617890B2 (ja) タンパク質チロシンホスファターゼ阻害物質及びその使用方法
TWI736566B (zh) Ｔｌｒ７/８拮抗劑及其用途
IL324078A (en) Fused ring compounds
EP4519260A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xdegraders
EP4519259A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
WO2023215449A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
CN112028891B (zh) 腺苷受体拮抗剂
CN112313220B (zh) Pd-l1拮抗剂化合物
WO2017025493A1 (en) Quinoline ezh2 inhibitors
KR20220077140A (ko) 프로스타글란딘 e2(pge2) ep4 수용체 길항제
WO2025059245A1 (en) Substituted oxoisoindolinyl piperidine-2,6-dione compounds
KR102918161B1 (ko) 신규한 화합물 및 이의 체크포인트 키나제 2 저해 용도
WO2025101571A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
WO2025101588A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
WO2025101575A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-x l degraders